1-7 of 7
Vali Papadimitrakopoulou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

Cristiana Sessa, Geoffrey I. Shapiro, Kapil N. Bhalla, Carolyn Britten, Karen S. Jacks, Monica Mita, Vali Papadimitrakopoulou, Tim Pluard, Thomas A. Samuel, Mikhail Akimov, Cornelia Quadt, Cristina Fernandez-Ibarra, Hong Lu, Stuart Bailey, Sandra Chica, Udai Banerji
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3671–3680.
https://doi.org/10.1158/1078-0432.CCR-12-3404
Published: 30 June 2013
View article titled, First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro

Daisuke Sano, Fumihiko Matsumoto, David R. Valdecanas, Mei Zhao, David P. Molkentine, Yoko Takahashi, Ehab Y. Hanna, Vali Papadimitrakopoulou, John Heymach, Luka Milas, Jeffrey N. Myers
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (7): 1815–1827.
https://doi.org/10.1158/1078-0432.CCR-10-2120
Published: 31 March 2011
View article titled, Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation <em>In Vivo</em> and <em>In Vitro</em>
Open the PDF for Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation <em>In Vivo</em> and <em>In Vitro</em> in another window
Includes: Supplementary data
Journal Articles

ΔNp63 Overexpression, Alone and in Combination with Other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia

Pierre Saintigny, Adel K. El-Naggar, Vali Papadimitrakopoulou, Hening Ren, You-Hong Fan, Lei Feng, J. Jack Lee, Edward S. Kim, Waun Ki Hong, Scott M. Lippman, Li Mao
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6284–6291.
https://doi.org/10.1158/1078-0432.CCR-09-0498
Published: 30 September 2009
View article titled, ΔNp63 Overexpression, Alone and in Combination with Other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia
Open the PDF for ΔNp63 Overexpression, Alone and in Combination with Other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia in another window
Journal Articles

Response of Non–Small Cell Lung Cancer Cells to the Inhibitors of Phosphatidylinositol 3-Kinase/Akt- and MAPK Kinase 4/c-Jun NH2-Terminal Kinase Pathways: An Effective Therapeutic Strategy for Lung Cancer

Ho-Young Lee, Seung-Hyun Oh, Young-Ah Suh, Jin Hyen Baek, Vali Papadimitrakopoulou, Suyun Huang, Waun Ki Hong
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 6065–6074.
https://doi.org/10.1158/1078-0432.CCR-05-0009
Published: 22 August 2005
View article titled, Response of Non–Small Cell Lung Cancer Cells to the Inhibitors of Phosphatidylinositol 3-Kinase/Akt- and MAPK Kinase 4/c-<em>Jun</em> NH<sub>2</sub>-Terminal Kinase Pathways: An Effective Therapeutic Strategy for Lung Cancer
Open the PDF for Response of Non–Small Cell Lung Cancer Cells to the Inhibitors of Phosphatidylinositol 3-Kinase/Akt- and MAPK Kinase 4/c-<em>Jun</em> NH<sub>2</sub>-Terminal Kinase Pathways: An Effective Therapeutic Strategy for Lung Cancer in another window
Journal Articles

Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors

Vali Papadimitrakopoulou, Sofia Agelaki, Hai T. Tran, Merrill Kies, Robert Gagel, Ralph Zinner, Edward Kim, Gregory Ayers, John Wright, Fadlo Khuri
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (11): 4151–4159.
https://doi.org/10.1158/1078-0432.CCR-04-1659
Published: 01 June 2005
View article titled, Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors
Open the PDF for Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors in another window
Journal Articles

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Fadlo R. Khuri, Bonnie S. Glisson, Edward S. Kim, Paul Statkevich, Peter F. Thall, Michael L. Meyers, Roy S. Herbst, Reginald F. Munden, Craig Tendler, Yali Zhu, Sandra Bangert, Elizabeth Thompson, Charles Lu, Xue-Mei Wang, Dong M. Shin, Merrill S. Kies, Vali Papadimitrakopoulou, Frank V. Fossella, Paul Kirschmeier, W. Robert Bishop, Waun Ki Hong
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (9): 2968–2976.
https://doi.org/10.1158/1078-0432.CCR-03-0412
Published: 06 May 2004
View article titled, Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors
Open the PDF for Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors in another window
Journal Articles

Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development : Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia

Joyce A. O’Shaughnessy, Gary J. Kelloff, Gary B. Gordon, Andrew J. Dannenberg, Waun Ki Hong, Carol J. Fabian, Caroline C. Sigman, Monica M. Bertagnolli, Steven P. Stratton, Stephen Lam, William G. Nelson, Frank L. Meyskens, David S. Alberts, Michele Follen, Anil K. Rustgi, Vali Papadimitrakopoulou, Peter T. Scardino, Adi F. Gazdar, Lee W. Wattenberg, Michael B. Sporn, Wael A. Sakr, Scott M. Lippman, Daniel D. Von Hoff
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (2): 314–346.
Published: 01 February 2002
View article titled, Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development : <subtitle>Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia</subtitle>
Open the PDF for Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development : <subtitle>Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia</subtitle> in another window